Market Overview

IGI Laboratories Completes Sixth ANDA Filing for 2013 Under Joint Drug Development And Commercialization Agreement

IGI Laboratories (NYSE MKT: IG) today announced it executed a license, development, supply and marketing agreement with a large multi-national pharmaceutical company.  In accordance with the confidentiality agreement in place, the name of the company remains undisclosed.  The agreement designates IGI Laboratories, Inc. (IGI) as the developer and manufacturer of a generic topical pharmaceutical drug product, which will be licensed, marketed and distributed in the United States by our partner, or its subsidiaries. The named product in the agreement was developed at IGI.  IGI has now filed the Abbreviated New Drug Application associated with the named generic pharmaceutical product.  In accordance with the agreement, our partner is required to pay IGI when certain milestones are met related to the filing and approval of the associated ANDA.  In addition, in accordance with the agreement, IGI will also receive a share of the profits following the approval and commercialization of the product.

See full press release

Posted-In: News Guidance Financing Contracts Asset Sales M&A Global

 

Most Popular

Related Articles (IG)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free